One of the first identified inhibitory checkpoints—CD152, also known as T lymphocyte-associated protein (CTLA-4)—has been shown to prevent expansion of CD4+ helper T cells, boost regulatory T cells, and promote a pro-tumour immuno-suppressive phenotype [4,5]. Here, CTLA4 is linked to neoplasm.